RxDoctor Payments Data

George Daniel, MD

Cardiovascular Disease · Boynton Beach, FLNPI 1194799502

Payments from drug & device makers

$27,182in general payments, 2019–2025

Across 409 payments — averaging $66.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Esperion Therapeutics, Inc.$12K
  • Abbott$4K
  • Edwards Lifesciences$3K
  • Boston Scientific$1K
  • Novartis$700
  • Merck$578
  • plus $6K from 43 others

What the payments were for

  • Consulting fees$2,00014%
  • Travel & lodging$2,15015%
  • Food & beverage$10,40070%
  • Education$2131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,182 in reported general payments places this provider in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$866,763
Medicare patients
1,690
Services billed
6,961

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan214$266,102
VyndamaxTafamidis12$251,908
EliquisApixaban208$232,498
XareltoRivaroxaban151$154,255
Repatha SureclickEvolocumab104$110,650
FarxigaDapagliflozin Propanediol50$70,179
BrilintaTicagrelor66$54,150
Repatha PushtronexEvolocumab30$22,062
Repatha SyringeEvolocumab17$21,477
Praluent PenAlirocumab31$20,175
Valsartan404$11,204
Metoprolol Succinate627$8,471
Rosuvastatin Calcium347$4,257
Atorvastatin Calcium442$4,097
Bumetanide134$3,806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$267$484,406220 claims
NovartisEntresto$700$266,102214 claims
Johnson & JohnsonXarelto$373$154,255151 claims
AstraZenecaFarxiga, Brilinta$238$124,329116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Boynton Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →